1 / 26

BORDERNETwork Training on

BORDERNETwork Training on. P ost- E xposure- P rophylaxis. Dr. med. Wolfgang Güthoff / Alexander Leffers, M.A. www.bordernet.eu. www.aidshilfe-potsdam.de.

opa
Télécharger la présentation

BORDERNETwork Training on

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. BORDERNETwork Training on Post-Exposure-Prophylaxis Dr. med. Wolfgang Güthoff / Alexander Leffers, M.A. www.bordernet.eu www.aidshilfe-potsdam.de

  2. This presentation arises from the BORDERNETwork project which has received funding from the European Union, in the framework of the Health Program, and co-funding of the Ministry of Environment, Health and Consumer Protection of the Federal State of Brandenburg. The sole responsibility of any use that may be made of the information lies with the authors (SPI, AIDS-Hilfe Potsdam e.V.)

  3. Table of Contents Transmission Conditions for PEP Guidelines on PEP Blood Control Problems with PEP

  4. PEP HIV - Exposure When? Injury with HIV contaminated instruments Wetting of open wounds and mucosa with HIV contaminated fluids Unprotected sex with an HIV infected person Use of HIV contaminated needles (needle sharing) Transfusion of HIV contaminated blood or blood products Postexpositionelle Prophylaxe der HIV-Infektion. Gemeinsame Empfehlung der Deutschen AIDS-Gesellschaft (DAIG e.V. und der Österreichischen AIDS-Gesellschaft (ÖAG) et al., in: Dtsch Med. Wochenschr 2009; 134: S 16-S 33.

  5. PEP - Guidelines • The ultimate goal of PEP is: • to suppress any viral replication that may occur, • to shift the biological advantage to the host cellular immune system to prevent or abort early infection http://www.who.int/hiv/pub/guidelines/PEP/en/ http://www.hivguidelines.org/wp-content/uploads/2009/05/pep_card.pdf http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5011a1.htm

  6. Occupational PEP Probability of Transmission Factors influencing transmission: Kind of transmitting material (Viral concentration is highest in the blood) Kind of exposure: Hollow needle Cut injury Open wound Exposure of mucosa Viral concentration from index person Postexpositionelle Prophylaxe der HIV-Infektion. Gemeinsame Empfehlung der Deutschen AIDS-Gesellschaft (DAIG e.V. und der Österreichischen AIDS-Gesellschaft (ÖAG) et al., in: Dtsch Med. Wochenschr 2009; 134: S 16-S 33.

  7. Occupational PEP Probability of Transmission Average risk: • Percutaneous 0.3% • Mucous membrane 0.1% • Non-intact skin <0.1% • Blood transmission 100% (non occupational course – unprotected sex 0,03 – 7,5%) Postexpositionelle Prophylaxe der HIV-Infektion. Gemeinsame Empfehlung der Deutschen AIDS-Gesellschaft (DAIG e.V. und der Österreichischen AIDS-Gesellschaft (ÖAG) et al., in: Dtsch Med. Wochenschr 2009; 134: S 16-S 33.

  8. Risk for an HIV-Transmission depending on Exposure in Relation to Average Risk Postexpositionelle Prophylaxe der HIV-Infektion. Gemeinsame Empfehlung der Deutschen AIDS-Gesellschaft (DAIG e.V. und der Österreichischen AIDS-Gesellschaft (ÖAG) et al., in: Dtsch Med. Wochenschr 2009; 134: S 16-S 33.

  9. Occupational PEP Probability of Transmission • High Risk • deep parenteral inoculation via hollow needle • parenteral inoculation with high viral titers • Less Risk • injuries via non-hollow needle • mucosal exposure/non-intact skin exposure • Risk not identified • intact skin exposure • exposure to urine, saliva, tears, sweat

  10. Exposure Risk Little information on efficacy of PEP in humans Seroconversion infrequent following occupational exposure to HIV-infected blood Use of Zidovudine (ZDV) was associated with an 81% decrease in the risk for HIV infection limitations include a small number of cases, and that cases and controls came from different cohorts (Cardo et al, NEJM 1997;337:1485-90.)

  11. PEP - Conditions • contact with relevant risk of transmission between an HIV-negative Person and an HIV- infected Person (Index person) • Negative HIV-Test in exposed Person is a condition for PEP • HIV- Rapid Test of Index person • HIV Rapid Test available?

  12. PEP - Counselling and Decision(two physicians should get knowledge and experience in this field in every hospital) Estimation of risk Decision for PEP: strongly encourage recommend offer do nothing (counselling is important that the exposed person is assured) Counsellingfor PEP encloses: no blood donation for 12 month safer sex until getting final HIV test after six month drugs do not have an apply for this indication written confirmation

  13. Occupational PEPImmediate Measures • Measurements at cut injuries or needle sticks • disinfection, wash it with soap and water • Mucosa membrane exposure • Douche of oral cavity with 70% alcohol: mouth wash 5 times for 15 seconds Douche of eyes with running water • Non intact skin • Wash with soap, water and antiseptic Postexpositionelle Prophylaxe der HIV-Infektion. Gemeinsame Empfehlung der Deutschen AIDS-Gesellschaft (DAIG e.V. und der Österreichischen AIDS-Gesellschaft (ÖAG) et al., in: Dtsch Med. Wochenschr 2009; 134: S 16-S 33.

  14. Post exposure Prophylaxis (PEP) PEP after occupational HIV-Exposition Transdermal injury with contaminated hollow needle  strongly encourage Superficial injury (f. e. with surgery needle)  offer Contact of damaged skin with blood  offer Contamination of intact skin  do not recommend Contamination of mucosa membrane with blood  recommend Contamination of mucosa membrane with urine or saliva  do not recommend Postexpositionelle Prophylaxe der HIV-Infektion. Gemeinsame Empfehlung der Deutschen AIDS-Gesellschaft (DAIG e.V. und der Österreichischen AIDS-Gesellschaft (ÖAG) et al., in: Dtsch Med. Wochenschr 2009; 134: S 16-S 33.

  15. PEP – when to start and time limits • Entry and Fusion 2h • DNA-Integration in nucleus 12h • Viral replication after another 12h • PEP within 24h (best - start within first 2h) • >72h after Exposition: PEP is not practical Replication of HIV and Targets of Therapy Postexpositionelle Prophylaxe der HIV-Infektion. Gemeinsame Empfehlung der Deutschen AIDS-Gesellschaft (DAIG e.V. und der Österreichischen AIDS-Gesellschaft (ÖAG) et al., in: Dtsch Med. Wochenschr 2009; 134: S 16-S 33.

  16. Medications for PEP(German – Austrian Guidelines) Postexpositionelle Prophylaxe der HIV-Infektion. Gemeinsame Empfehlung der Deutschen AIDS-Gesellschaft (DAIG e.V. und der Österreichischen AIDS-Gesellschaft (ÖAG) et al., in: Dtsch Med. Wochenschr 2009; 134: S 16-S 33.

  17. European Guidelines • HIV- rapid test from Index person • If Index person’s HIV-RNA > 1000 copies/ml – testing of drug resistance • Start PEP if possible within 4h and not later then 48h • Duration: 4 weeks • Medication: • Truvada (TDF/FTC)1 x 1 pillAlternative: Combivir (ZDV/3TC) 2 x 1 pill + • Kaletra (LPVr) 2 x 2 pillsAlternative: Invirase 500(SQV) 2 x2 capsules and Norvir (RTV) 2 x 100mg Postexpositionelle Prophylaxe der HIV-Infektion. Gemeinsame Empfehlung der Deutschen AIDS-Gesellschaft (DAIG e.V. und der Österreichischen AIDS-Gesellschaft (ÖAG) et al., in: Dtsch Med. Wochenschr 2009; 134: S 16-S 33.

  18. Blood Controls Serologic control (HIV, possible HBV, HCV): • at the start • after 6 weeks, • after 3 month • after 6 month Laboratory tests: • at the start, after 2 weeks and after 4 weeks: Blood count, liver enzymes, kidney function, blood sugar, urine

  19. Problems regarding HIV – PEP Pregnancy and lactation period No substance is harmless! PEP only at high risk Experience only with Retrovir and Epivir Sustiva (Efavirenz) is contraindicated!

  20. Problems regarding HIV – PEP • Period between exposition and starting PEP not longer than 24 h

  21. Problems regarding HIV – PEP • High risk through massive inoculation ofinfections material

  22. Problems regarding HIV – PEP • Strong side effects of HAART (mental – Efavirenz)

  23. Problems regarding HIV – PEP • Index person gets HAART and drug resistance is probable • Course of CD4 cells • Opportunistic infections (OI)

  24. PEP - Index person • HIV-Infection known? • How fast is an HIV-test possible? • HIV- rapid tests every time for every physician available?

  25. Treatment Algorithm Did an exposure to a potentially HIV-infected fluid occur? • No indication of PEP • No follow-up needed Stop PEP Continue PEP for 4 weeks NO YES • Serological test of source patient is confirmed HIV negative • no evidence of acute retroviral syndrome • Serological test of source patient is confirmed HIV positive • Evidence of acute retroviral syndrome occurs • Source patient is unknown, unwilling etc. • No indication of PEP • No follow-up needed Did a significant risk of transmission of HIV occur? (Contact of a HIV negative person with an HIV positive person (index person/source patient) NO YES • PEP not indicated • Follow-up • HIV testing Is the patient presenting within ideally 2 hours, not later than 72 hours of the exposure? NO • Initiation of PEP regimen: • PEP within 24h (best - start within first 2h) • HIV monitoring YES Can the source patient be interviewed? If yes: Individual benefit-risk assessment If yes: interview on HIV status or infection risk, resp. test/rapid test on HIV If no: belongs the source patient to a high risk group (with high prevalence) If no: PEP not indicated Adopted from: New York State Department of Health/ AIDS Institute: Recommendations for HIV Postexposure Prophylaxis (PEP) URL: http://www.hivguidelines.org/wp-content/uploads/2009/05/pep_card.pdf Adopted from: Postexpositionelle Prophylaxe der HIV-Infektion. Gemeinsame Empfehlung der Deutschen AIDS-Gesellschaft (DAIG e.V.) und der Österreichischen AIDS-Gesellschaft (ÖAG) et al. in: Dtsch Med. Wochenschr 2009; 134: S 16-S 33.

More Related